相关临床试验
288
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1989
进行中（未招募）
3
1.0%
已完成
275
95.5%
尚未招募
4
1.4%
招募中
1
0.3%
暂停
1
0.3%
终止
2
0.7%
Unknown
2
0.7%
暂无批准数据
- A child who attended two childcare centres in the Launceston area has been diagnosed with tuberculosis, with the case last attending Goodstart Early Learning Centre in Kings Meadows in mid-July. - Tasmania's Department of Health and clinical specialists have identified potentially exposed staff and children, offering free precautionary testing coordinated through the centres. - Health authorities describe the risk of TB transmission as low and an isolated case, noting the disease can be cured with antibiotics. - Between 10 and 20 TB cases are diagnosed in Tasmania each year, while tuberculosis causes an estimated 1.3 million deaths worldwide annually.
- Elliot MacDonald, 35, diagnosed with grade four glioblastoma and given 12–18 months to live, raised £150,000 in 48 hours to pursue treatments unavailable on the NHS. - Jack Rawding-Revell, 25, diagnosed with inoperable glioblastoma, is seeking experimental treatment in early trials in the Netherlands and Switzerland that he says could be "five to 10 times more potent." - Experts caution that immunotherapies and other emerging treatments show promise but lack sufficient clinical evidence, while brain cancer receives only about 3% of UK cancer research funding. - The Department of Health cites the National Cancer Plan and the Rare Cancers Act as measures to improve survival and boost research and clinical trials for brain cancer.
- Ireland's Health Referral Scheme goes live nationally from 1 September 2026, offering a health-led response for first-time personal drug possession offenders. - Eligible individuals found in possession of drugs for personal use will be referred by An Garda Síochána to the HSE for brief intervention and assessment. - The scheme reflects the Government's commitment to treating drug use as a public health issue, in line with the Citizens Assembly on Drug Use recommendations. - The Department of Health has provided €700,000 to the HSE to establish a network of SAOR practitioners to deliver assessments and interventions.
- The Philippine Food and Drug Administration is institutionalizing a "Green Lane" regulatory pathway to accelerate approvals for local pharmaceutical manufacturers producing essential medicines while maintaining safety standards. - The Philippine Chamber of Pharmaceutical Industry, representing 90 companies including Unilab Inc., strongly supports the initiative as a critical reform to strengthen domestic pharmaceutical manufacturing capabilities. - The Green Lane framework includes streamlined review timelines and clearer documentation requirements, drawing from proven regulatory models in Singapore, India, and China. - Local manufacturers demonstrated their critical role during COVID-19 by being first responders to sudden demand spikes, highlighting the importance of reducing over-reliance on imported medicines and APIs.
- Hong Kong's Department of Health has introduced one-on-one pre-new drug application meetings for companies seeking registration under the "1+" mechanism, effective immediately and offered free of charge. - The new consultation service includes company-oriented meetings for first-time applicants and product-specific sessions to provide tailored regulatory guidance and streamline submission processes. - Since implementation in November 2023, the "1+" mechanism has approved 16 new drugs with seven listed in the Hospital Authority Drug Formulary, while receiving over 700 inquiries from 180+ pharmaceutical companies. - The initiative supports Hong Kong's broader regulatory reform agenda, including plans for a primary evaluation system beginning in 2026 and establishment of the Hong Kong Centre for Medical Products Regulation by end of 2026.
- Hong Kong has approved four new drugs under its accelerated "1+" approval mechanism, including a treatment for primary immunoglobulin A nephropathy and therapies for thyroid eye disease, cervical cancer, and severe hemophilia. - Since implementation in November 2023, the "1+" mechanism has approved 15 new drugs total, with seven already listed in the Hospital Authority Drug Formulary. - The mechanism allows new drugs to gain Hong Kong approval with support from just one reference regulatory authority instead of two, significantly streamlining the approval process. - Hong Kong plans to establish the Centre for Medical Products Regulation by end of 2025 and implement "primary evaluation" for drug registration beginning next year.
- Hong Kong will launch its own drug and medical device regulator by late 2026, marking a significant shift from the current secondary evaluation system that requires approval from at least two overseas regulators. - The Hong Kong Centre for Medical Products Regulation will implement primary evaluation in phases starting 2026, enabling fast-track approval of homegrown drugs and medical devices based on clinical trial data without foreign regulatory dependence. - Since 2023, 11 life-saving drugs including cancer treatments have been approved under the interim "1+" mechanism requiring only one overseas regulator's approval, demonstrating progress toward regulatory independence. - The city plans to apply for membership in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use in 2027 to achieve international recognition of its regulatory framework.
- Hong Kong's Department of Health is launching consultation services to help pharmaceutical companies navigate the "1+" drug registration mechanism, starting with an online seminar on March 31, 2025. - The "1+" mechanism, implemented in November 2023, allows new drugs to be registered with approval from just one reference regulatory authority instead of two, significantly expediting market access. - Five new medications registered under the "1+" system have already been added to the Hospital Authority's formulary, resulting in 30-35% price reductions and annual savings of HK$15-24 million.
- Philippines reports a dramatic 56% increase in dengue cases during the first six weeks of 2025, with over 43,000 cases recorded across key regions including Calabarzon, Metro Manila, and Central Luzon. - Senator Nancy Binay calls for expedited evaluation of Takeda's TAK-003 dengue vaccine, which has already received approval in more than 40 countries worldwide. - Current dengue prevention strategies, including the long-standing 5S approach, are being questioned as potentially insufficient amid the rising case numbers.
- A clinical trial in the Philippines is evaluating virgin coconut oil (VCO) as a potential treatment for COVID-19, with results anticipated by December. - The Department of Health (DOH) is overseeing the VCO trial, alongside another trial investigating Avigan, an anti-viral drug. - The VCO trial aims to determine the efficacy of VCO in managing symptoms and potentially reducing the severity of COVID-19 infections. - The study's findings could offer an affordable and accessible treatment option for COVID-19, particularly in resource-limited settings.
